Related references
Note: Only part of the references are listed.Immune-Guided Therapy of COVID-19
Gianfranco Ferraccioli et al.
CANCER IMMUNOLOGY RESEARCH (2022)
Plasma Von Willebrand Factor Levels Predict Survival in COVID-19 Patients Across the Entire Spectrum of Disease Severity
Vineeth Varghese Thomas et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2022)
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
A. Cortegiani et al.
PULMONOLOGY (2021)
Major reduction of NKT cells in patients with severe COVID-19 pneumonia
Maria Antonella Zingaropoli et al.
CLINICAL IMMUNOLOGY (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Carlos Salama et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation
Arya Zarinsefat et al.
FRONTIERS IN GENETICS (2021)
Comparative assessment of mortality risk factors between admission and follow-up models among patients hospitalized with COVID-19
Felippe Lazar Neto et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled
Delia Goletti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Anthony C. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
An open label trial of anakinra to prevent respiratory failure in COVID-19
Evdoxia Kyriazopoulou et al.
ELIFE (2021)
Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia
Maria Antonella Zingaropoli et al.
FRONTIERS IN IMMUNOLOGY (2021)
Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals
Anuradha Rajamanickam et al.
SCIENTIFIC REPORTS (2021)
Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study
Gianluca Russo et al.
PLOS ONE (2021)
Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19
Shoji Hashimoto et al.
FRONTIERS IN MEDICINE (2021)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou et al.
NATURE (2020)
Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19
Wenhua Liang et al.
JAMA INTERNAL MEDICINE (2020)
Pharmaco-Immunomodulatory Therapy in COVID-19
John G. Rizk et al.
DRUGS (2020)
Tocilizumab for severe COVID-19: a systematic review and meta-analysis
Shao-Huan Lan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19
Qing Ye et al.
JOURNAL OF INFECTION (2020)
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19
Sarah C. J. Jorgensen et al.
PHARMACOTHERAPY (2020)
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm
Chuang Guo et al.
NATURE COMMUNICATIONS (2020)
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Francesco Perrone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology
Jose Gomez-Rial et al.
FRONTIERS IN IMMUNOLOGY (2020)
Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness
Camilla Tincati et al.
FRONTIERS IN IMMUNOLOGY (2020)
The importance of patients' case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease
Antonella d'Arminio Monforte et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Giovanni Guaraldi et al.
LANCET RHEUMATOLOGY (2020)
Differential expression and predictive value of monocyte scavenger receptor CD163 in populations with different tuberculosis infection statuses
Qiandian Liu et al.
BMC INFECTIOUS DISEASES (2019)
Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment
Saverio G. Parisi et al.
MEDICAL MICROBIOLOGY AND IMMUNOLOGY (2018)
Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort
Serena Vita et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2017)
Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection
Claudia Mascia et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2017)
Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals
Troels Bygum Knudsen et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Soluble CD163 Made by Monocyte/Macrophages Is a Novel Marker of HIV Activity in Early and Chronic Infection Prior to and After Antiretroviral Therapy
Tricia H. Burdo et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Differential Expression of CD163 on Monocyte Subsets in Healthy and HIV-1 Infected Individuals
Emma Tippett et al.
PLOS ONE (2011)
Identification of the haemoglobin scavenger receptor
M Kristiansen et al.
NATURE (2001)
Share Paper
